MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Investigating glutamate toxicity associated to Park2 mutations in pre-clinical models of Parkinson’s Disease

I. Trezzi, M. Regoni, M. Magni, M. Schröter, A. Buccino, D. Lopez, G. Faustini, L. Murro, F. Biella, E. Frattini, R. Silipigni, M. Passafaro, A. Bellucci, M. Bortolozzi, J. Sassone, A. Di Fonzo (Milan, Italy)

Meeting: 2023 International Congress

Abstract Number: 1491

Keywords: Glutamate, Parkinson’s, Stem cells. See also Human embryonic stem cells

Category: Parkinson's Disease: Molecular Mechanisms of Disease

Objective: To generate and characterize induced pluripotent stem cells (iPSCs)-derived in vitro cellular models of Autosomal Recessive Juvenile Parkinsonism (ARJP) carrying Park2 mutations with a focus on the study of glutamate toxicity.

Background: Park2 encodes for a ubiquitin-ligase protein whose mutation upregulates Gluk2, a subunit of the glutamate kainate receptor (KAR) [1], expressed in astrocytes and SNpc neurons. KAR upregulation may induce neuronal and glial excitotoxicity, leading to an early synaptopathy, neuroinflamation and consequently neurodegeneration.

Method: Fibroblasts and lymphocytes from Park2 patients and age-matched controls were reprogrammed into iPSCs and further differentiated into dopaminergic neurons [2] and astrocytes [3]. Mesencephalic organoids were also generated and differentiated [4]. Protein expression profile was analysed through western blot (WB), qPCR and immunofluorescence (IF). Electrophysiology assessment was performed on dopaminergic neurons and midbrain organoids in order to better functionally profile these models.

Results: We found Gluk2 significantly overexpressed in PARK2 midbrain organoids and astrocytes. Calcium-imaging and HD-MEAs showed an oscillatory augmented reactivity in PARK2 midbrain organoids. We also found a significant tyrosine hydroxylase (TH) overexpression in PARK2 dopaminergic neurons and midbrain organoids and a reactive astrocytosis in PARK2 astrocytes and midbrain organoids, along with a reduced excitatory amino acid transporter 2 (EAAT2), the astrocytic glutamate transporter, expression.

Conclusion: Our study was able to confirm in human-derived cellular models the previously demonstrated link between Park2 mutations and KAR upregulation [1]. The increased neuronal activity found in PARK2 midbrain organoids may be the expression of glutamate dysregulation. Two innovative findings emerged from this study: an increased TH expression in PARK2, matching the altered dopamine turnover related to such mutations and the contribution of astrocytes in Park2-associated excitotoxicity and neurodegeneration through an altered glutamate turnover. Further studies are required to establish Park2 role in TH expression and regulation, in astrocytic reactivity induction and in glutamate toxicity.

References: [1] Maraschi A., Ciammola A., Folci A. et al. Parkin regulates kainate receptors by interacting with the GluK2 subunit. Nat Commun. (2014): 5:5182.
[2] Zhang P., Xia N., Reijo Pera RA. Directed dopaminergic neuron differentiation from human pluripotent stem cells. J Vis Exp. (2014): (91):51737.
[3] Santos R., Vadodaria KC., Jaeger BN. et al. Differentiation of Inflammation-Responsive Astrocytes from Glial Progenitors Generated from Human Induced Pluripotent Stem Cells. Stem Cell Reports. (2017): 1757-1769.
[4] Lancaster MA., Knoblich JA. Generation of cerebral organoids from human pluripotent stem cells. Nat Protoc. (2014): 2329-40.

To cite this abstract in AMA style:

I. Trezzi, M. Regoni, M. Magni, M. Schröter, A. Buccino, D. Lopez, G. Faustini, L. Murro, F. Biella, E. Frattini, R. Silipigni, M. Passafaro, A. Bellucci, M. Bortolozzi, J. Sassone, A. Di Fonzo. Investigating glutamate toxicity associated to Park2 mutations in pre-clinical models of Parkinson’s Disease [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/investigating-glutamate-toxicity-associated-to-park2-mutations-in-pre-clinical-models-of-parkinsons-disease/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/investigating-glutamate-toxicity-associated-to-park2-mutations-in-pre-clinical-models-of-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley